[go: up one dir, main page]

HUP9802324A3 - Use of ribavirin and interferon alpha for the treatment of hepatitis c - Google Patents

Use of ribavirin and interferon alpha for the treatment of hepatitis c

Info

Publication number
HUP9802324A3
HUP9802324A3 HU9802324A HUP9802324A HUP9802324A3 HU P9802324 A3 HUP9802324 A3 HU P9802324A3 HU 9802324 A HU9802324 A HU 9802324A HU P9802324 A HUP9802324 A HU P9802324A HU P9802324 A3 HUP9802324 A3 HU P9802324A3
Authority
HU
Hungary
Prior art keywords
ribavirin
hepatitis
treatment
interferon alpha
interferon
Prior art date
Application number
HU9802324A
Other languages
English (en)
Original Assignee
Schering Corp Kenilwort
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp Kenilwort filed Critical Schering Corp Kenilwort
Publication of HUP9802324A2 publication Critical patent/HUP9802324A2/hu
Publication of HUP9802324A3 publication Critical patent/HUP9802324A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU9802324A 1995-05-19 1996-05-15 Use of ribavirin and interferon alpha for the treatment of hepatitis c HUP9802324A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/444,584 US6387365B1 (en) 1995-05-19 1995-05-19 Combination therapy for chronic hepatitis C infection

Publications (2)

Publication Number Publication Date
HUP9802324A2 HUP9802324A2 (hu) 1999-05-28
HUP9802324A3 true HUP9802324A3 (en) 2001-04-28

Family

ID=23765515

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802324A HUP9802324A3 (en) 1995-05-19 1996-05-15 Use of ribavirin and interferon alpha for the treatment of hepatitis c

Country Status (15)

Country Link
US (2) US6387365B1 (hu)
EP (2) EP1005868A1 (hu)
JP (1) JPH10506640A (hu)
KR (1) KR19990014925A (hu)
CN (1) CN1190895A (hu)
AU (1) AU5919296A (hu)
BR (1) BR9608758A (hu)
CA (1) CA2221314A1 (hu)
CZ (1) CZ365497A3 (hu)
HU (1) HUP9802324A3 (hu)
NO (1) NO975309D0 (hu)
NZ (1) NZ309217A (hu)
PL (1) PL323477A1 (hu)
SK (1) SK155997A3 (hu)
WO (1) WO1996036351A1 (hu)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2329474C (en) 1995-11-02 2002-02-26 Schering Corporation Continuous low-dose cytokine infusion therapy
JP3416147B2 (ja) * 1996-01-23 2003-06-16 アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド 活性化ｔリンパ球におけるリバビリン及びリバビリン類似体によるｔｈ１型／ｔｈ２型サイトカインの発現の調節
DE69712316T2 (de) * 1996-01-23 2003-01-02 Icn Pharmaceuticals, Inc. Modulation der th1/th2 cytokinexpression durch ribavirin in aktivierten t-lymphozyten
US20020137696A1 (en) * 1996-01-23 2002-09-26 Robert Tam Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes
DK0886527T3 (da) * 1996-02-28 2002-03-04 Unihart Corp Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon
WO1998019670A2 (en) * 1996-11-01 1998-05-14 Thomas Najarian Combination therapy of hepatitis c infections
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
DK0903148T3 (da) * 1997-09-21 2001-12-17 Schering Corp Kombinationsterapi til udryddelse af påviselig HCV-RNA hos patienter med kronisk hepatitis C infektion
ZA9811726B (en) * 1997-12-22 1999-06-21 Schering Corp Orally administrable solid ribavirin dosage forms and process for making them
SK288038B6 (en) * 1998-05-15 2013-01-02 Merck Sharp & Dohme Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection
KR20050055053A (ko) * 1998-06-08 2005-06-10 에프. 호프만-라 로슈 아게 만성 Ｃ형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-α 및 리바비린의 용도
EP1109580A4 (en) * 1998-09-04 2004-05-26 Viropharma Inc METHOD FOR TREATING OR PREVENTING VIRAL INFECTIONS AND RELATED DISEASES
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
BR9915546A (pt) * 1998-10-16 2001-08-14 Schering Corp Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
AU2156900A (en) * 1998-12-18 2000-07-12 Schering Corporation Ribavirin-interferon alfa induction hcv combination therapy
EP1140143A2 (en) * 1998-12-18 2001-10-10 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
NZ517634A (en) * 1999-12-23 2004-06-25 Icn Pharmaceuticals Compositions and methods for L-nucleosides, L-nucleotides, and their analogs
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
US6924270B2 (en) * 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
CZ2003311A3 (cs) * 2000-08-02 2004-04-14 Ortho-Mcneil Pharmaceutical, Inc. Protivirová a protinádorová terapie za použití erythropoetinu
US20060024270A1 (en) * 2000-08-23 2006-02-02 The New York Hospital Medical Center Of Queens Compositions and methods for preventing or treating encephalitis with interferon
US6946125B2 (en) * 2000-08-23 2005-09-20 The New York Hospital Medical Center Of Queens Methods of treating West Nile virus infection
WO2002032414A2 (en) * 2000-10-18 2002-04-25 Schering Corporation Ribavirin-pegylated interferon alfa hcv combination therapy
US6720000B2 (en) 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
EP1401477A4 (en) * 2001-05-25 2005-02-02 Human Genome Sciences CHIMIOKINE BETA-1 HYBRID PROTEINS
AU2002346686A1 (en) * 2001-12-07 2003-06-23 Intermune, Inc. Compositions and method for treating hepatitis virus infection
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
ES2425738T3 (es) * 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
WO2004004653A2 (en) * 2002-07-02 2004-01-15 Corcept Therapeutics, Inc. Methods for treating psychosis associated with interferon-alpha therapy
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7538094B2 (en) 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
JP2004143113A (ja) * 2002-10-25 2004-05-20 Shinya Nakajima インターフェロン製剤及びその投与システム
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
MXPA05010419A (es) * 2003-03-28 2006-05-31 Pharmasset Inc Compuestos para el tratamiento de infecciones por flaviviridae.
TW200523270A (en) 2003-07-18 2005-07-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV ns3-ns4a protease
JPWO2006033453A1 (ja) * 2004-09-22 2008-05-15 学校法人順天堂 インターフェロン作用物質の活性増強剤
US7723310B2 (en) 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
EP1850862A2 (en) * 2005-01-19 2007-11-07 Avigenics, Inc. Methods of treating disease with glycosylated interferon
JP5034944B2 (ja) * 2005-07-27 2012-09-26 味の素株式会社 インターフェロン作用物質の活性増強剤
EP2356990A3 (en) 2006-08-02 2011-10-19 University of Oxford Liposome treatment of viral infections
US20080131398A1 (en) * 2006-08-21 2008-06-05 United Therapeutics Corporation Combination therapy for treatment of viral infections
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CN101820887A (zh) * 2007-07-25 2010-09-01 拜奥雷克斯治疗公司 干扰素控释药品以及使用相同药品治疗hcv感染
WO2009118658A2 (en) * 2008-03-26 2009-10-01 University Of Oxford Endoplasmic reticulum targeting liposomes
PE20110343A1 (es) * 2008-09-17 2011-06-25 Boehringer Ingelheim Int Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina
JP2012521981A (ja) * 2009-03-27 2012-09-20 ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード コレステロールレベル低下リポソーム
EP2459211A1 (en) 2009-07-31 2012-06-06 Medtronic, Inc. Continuous subcutaneous administration of interferon- to hepatitis c infected patients
US8822496B2 (en) 2009-10-30 2014-09-02 Boehringer Ingelheim International Gmbh Dosage regimens for HCV combination therapy
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
CN104436197A (zh) 2011-10-21 2015-03-25 艾伯维公司 至少两种直接作用抗病毒剂的组合产品
WO2013116592A1 (en) * 2012-02-01 2013-08-08 Kadmon Pharmaceuticals, Llc Once daily treatment of hepatitis c with ribavirin and taribavirin
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof

Also Published As

Publication number Publication date
AU5919296A (en) 1996-11-29
CN1190895A (zh) 1998-08-19
NZ309217A (en) 2000-08-25
WO1996036351A1 (en) 1996-11-21
CA2221314A1 (en) 1996-11-21
JPH10506640A (ja) 1998-06-30
EP1005868A1 (en) 2000-06-07
KR19990014925A (ko) 1999-02-25
US6299872B1 (en) 2001-10-09
EP0707855A2 (en) 1996-04-24
PL323477A1 (en) 1998-03-30
NO975309L (no) 1997-11-19
EP0707855A3 (en) 1996-11-27
HUP9802324A2 (hu) 1999-05-28
NO975309D0 (no) 1997-11-19
BR9608758A (pt) 1999-07-06
SK155997A3 (en) 1998-10-07
US6387365B1 (en) 2002-05-14
MX9708885A (es) 1998-03-31
CZ365497A3 (cs) 1998-07-15

Similar Documents

Publication Publication Date Title
HUP9802324A3 (en) Use of ribavirin and interferon alpha for the treatment of hepatitis c
HU228218B1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
GB9609932D0 (en) Use of IL-12 and IFN alpha for the treatment of infectious diseases
AU6588598A (en) Treatment of hepatitis b infection with thymosin alpha 1 and famciclovir
HUP9900929A3 (en) Methods for retreatment of patients afflicted with hepatitis c using consensus interferon
IL129352A0 (en) Benzimidazole-2- carbamates for the treatment of viral infections and cancer
ZA896864B (en) Method and composition for the treatment and prevention of viral infections
AU5687896A (en) Use of alpha 1L-agonists in the treatment of incontinence
IL112041A0 (en) Methods of inhibiting atrophy of the skin and vagina
KR100321237B1 (ko) 적층구조물
EP0719791A3 (en) Drugs for the treatment of restenosis and arterial sclerosis
EP0973510A4 (en) USE OF AMANTADINE FOR TREATING HEPATITIS C
ZA913949B (en) Diagnosis and treatment of viral hepatitis
AP9300555A0 (en) Therapeutic agent and its use
EP0786001A4 (en) CHEMOKIN-LIKE PROTEINS AND THEIR USE
EP0702080A3 (en) Azeotropic compositions containing octamethyltrisiloxane and n-propoxypropanol
GB9304746D0 (en) Treatment of viral infections
IL115320A0 (en) Retinoyloxy (substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
IL113992A0 (en) Use of copolymer-1
EP0656116A4 (en) METHOD FOR MONITORING THE EFFECTIVENESS OF INTERFERON THERAPY ON HEPATITIS-C INFECTED INDIVIDURES.
ZA988519B (en) Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
HU9301621D0 (en) Treatment of gas flow
EP0490250A3 (en) Use of interferon and an antimalarial agent for the treatment of malarial infections
ZA932603B (en) Treatment of hepatitis with GM-CSF
SI1077068T1 (en) Utilization of interferon alpha 5 in the treatment of viral hepatopathies